{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:36:31Z","timestamp":1794947791707,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1136\/ijgc-2024-005982","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:25:19Z","timestamp":1730741119000},"page":"1677-1684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-6623","authenticated-orcid":false,"given":"Jalid","family":"Sehouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0873-4686","authenticated-orcid":false,"given":"Jolijn","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros","family":"Glaspool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Khoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0711-1021","authenticated-orcid":false,"given":"Josee-Lyne","family":"Ethier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9663-5005","authenticated-orcid":false,"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Seebacher-Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-9232","authenticated-orcid":false,"given":"Paul A","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-721X","authenticated-orcid":false,"given":"Toon","family":"van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Chavez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Hranovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9260-3225","authenticated-orcid":false,"given":"Sharon","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8693-7299","authenticated-orcid":false,"given":"Christianne A R","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Alejandro","family":"Rauh-Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-4345","authenticated-orcid":false,"given":"Alejandro","family":"Perez Fidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8201-9490","authenticated-orcid":false,"given":"Noriko","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Rosengarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Ik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asima","family":"Mukopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Piovano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise C","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-0175","authenticated-orcid":false,"given":"Kristina","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Croke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Bookman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005982_bb0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2017.0762","article-title":"The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population","volume":"3","author":"Unger","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0015","doi-asserted-by":"crossref","first-page":"100252","DOI":"10.1016\/j.lana.2022.100252","article-title":"Race\/ethnicity reporting and representation in US clinical trials: A cohort study","volume":"11","author":"Turner","year":"2022","journal-title":"Lancet Reg Health - Americas"},{"key":"10.1136\/ijgc-2024-005982_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.326.7401.1244","article-title":"Representation of South Asian people in randomised clinical trials: analysis of trials\u2019 data","volume":"326","author":"Mason","year":"2003","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2024-005982_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ygyno.2023.10.017","article-title":"Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement","volume":"179","author":"Girda","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jnci\/djaa156","article-title":"Revisiting Barriers to Clinical Trials Accrual","volume":"113","author":"Brundage","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2024-005982_bb0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JOP.2017.025288","article-title":"Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years","volume":"14","author":"Duma","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1136\/ijgc-2024-005982_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0045","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2024-005982_bb0050","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1200\/OP.20.01108","article-title":"Cancer Disparities and Black American Representation in Clinical Trials Leading to the Approval of Oral Chemotherapy Drugs in the United States Between 2009 and 2019","volume":"17","author":"Ajewole","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1136\/ijgc-2024-005982_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33205","article-title":"Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies","volume":"4","author":"Aldrighetti","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2024-005982_bb0060","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.15585\/mmwr.mm6748a1","article-title":"Uterine Cancer Incidence and Mortality \u2014 United States, 1999\u20132016","volume":"67","author":"Henley","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1136\/ijgc-2024-005982_bb0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2022.0009","article-title":"Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype","volume":"8","author":"Clarke","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpt.61","article-title":"Racial\/ethnic differences in drug disposition and response: review of recently approved drugs","volume":"97","author":"Ramamoorthy","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ijgc-2024-005982_bb0075","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1377\/hlthaff.2021.01432","article-title":"Despite The FDA\u2019s Five-Year Plan, Black Patients Remain Inadequately Represented In Clinical Trials For Drugs","volume":"41","author":"Green","year":"2022","journal-title":"Health Aff (Millwood)"},{"key":"10.1136\/ijgc-2024-005982_bb0080","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.28574","article-title":"Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: Enhancing minority participation in clinical trials (EMPaCT)","volume":"120","author":"Durant","year":"2014","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2024-005982_bb0085","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.32755","article-title":"Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials","volume":"126","author":"Niranjan","year":"2020","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2024-005982_bb0090","first-page":"155","article-title":"American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care","volume":"39","author":"Pennell","year":"2021","journal-title":"J C O"},{"key":"10.1136\/ijgc-2024-005982_bb0095","author":"World Health Organization (WHO)","year":"2023","journal-title":"Public consultation on who guidance for best practices for clinical trials"},{"key":"10.1136\/ijgc-2024-005982_bb0100","unstructured":"GCIG . CCCC-cr 2024. Available: https:\/\/gcigtrials.org [Accessed 27 Mar 2024]."},{"key":"10.1136\/ijgc-2024-005982_bb0105","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/ijgc-2021-002422","article-title":"The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries","volume":"31","author":"McCormack","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005982_bb0110","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0115","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0120","author":"US Department of Health and Human Services, US Food and Drug Administration","year":"2016","journal-title":"Collection of race and ethnicity data in clinical trials guidance for industry and food and drug administration staff clinical medical preface public comment"},{"key":"10.1136\/ijgc-2024-005982_bb0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2024-005982_bb0130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/djaa155","article-title":"'When Offered to Participate': A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials","volume":"113","author":"Unger","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2024-005982_bb0135","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0140","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0145","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.1996.14.4.1364","article-title":"Reducing patient eligibility criteria in cancer clinical trials","volume":"14","author":"George","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0150","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2021.1307","article-title":"African American participation in cancer clinical trials","volume":"15","author":"Swaby","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"10.1136\/ijgc-2024-005982_bb0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaoncol.2019.4720","article-title":"Racial Disparities in Patient-Reported Measures of Physician Cultural Competency Among Cancer Survivors in the United States","volume":"6","author":"Butler","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0160","doi-asserted-by":"crossref","first-page":"e1753","DOI":"10.1200\/OP.21.00100","article-title":"Association of a Lay Health Worker-Led Intervention on Goals of Care, Quality of Life, and Clinical Trial Participation Among Low-Income and Minority Adults With Cancer","volume":"17","author":"Patel","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1136\/ijgc-2024-005982_bb0165","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JOP.2015.008946","article-title":"Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials","volume":"12","author":"Fouad","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1136\/ijgc-2024-005982_bb0170","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s13187-019-01650-y","article-title":"Overcoming Barriers: Evidence-Based Strategies to Increase Enrollment of Underrepresented Populations in Cancer Therapeutic Clinical Trials-a Narrative Review","volume":"35","author":"Vuong","year":"2020","journal-title":"J Cancer Educ"},{"key":"10.1136\/ijgc-2024-005982_bb0175","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2015.63.2257","article-title":"Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials","volume":"34","author":"Meropol","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08731-6","article-title":"Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany","volume":"21","author":"Dimitrova","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2024-005982_bb0185","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0090-8258(22)01231-8","article-title":"Leveling the playing field: Identifying barriers and patterns of endometrial cancer clinical trial enrollment for underrepresented groups (013)","volume":"166","author":"Lee","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003758","article-title":"Evaluating the frequency of English language requirements in clinical trial eligibility criteria: A systematic analysis using ClinicalTrials.gov","volume":"18","author":"Muthukumar","year":"2021","journal-title":"PLoS Med"},{"key":"10.1136\/ijgc-2024-005982_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygyno.2023.08.011","article-title":"Telehealth utilization in gynecologic oncology clinical trials","volume":"177","author":"Andriani","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0200","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMp2107331","article-title":"Integrating research into community practice\u2014Toward increased diversity in clinical trials","volume":"385","author":"Woodcock","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005982_bb0205","doi-asserted-by":"crossref","first-page":"100532","DOI":"10.1016\/j.conctc.2020.100532","article-title":"Operational strategies in US cancer centers of excellence that support the successful accrual of racial and ethnic minorities in clinical trials","volume":"17","author":"Regnante","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1136\/ijgc-2024-005982_bb0210","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1634\/theoncologist.2019-0146","article-title":"Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention","volume":"24","author":"Nipp","year":"2019","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2024-005982_bb0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01132","article-title":"Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement","volume":"36","author":"Winkfield","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005982_bb0220","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s40615-016-0283-3","article-title":"Discrepancies in Race and Ethnicity Documentation: a Potential Barrier in Identifying Racial and Ethnic Disparities","volume":"4","author":"Maga\u00f1a L\u00f3pez","year":"2016","journal-title":"J Racial Ethn Health Disparities"},{"key":"10.1136\/ijgc-2024-005982_bb0225","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2105\/AJPH.92.9.1471","article-title":"Self-reported vs administrative race\/ethnicity data and study results","volume":"92","author":"Boehmer","year":"2002","journal-title":"Am J Public Health"},{"key":"10.1136\/ijgc-2024-005982_bb0230","doi-asserted-by":"crossref","first-page":"101072","DOI":"10.1016\/j.scp.2023.101072","article-title":"Diversified innovations in the health sciences: Proposal for a Diversity Minimal Item Set (DiMIS)","volume":"33","author":"Stadler","year":"2023","journal-title":"Sustain Chem Pharm"},{"key":"10.1136\/ijgc-2024-005982_bb0235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clon.2020.06.016","article-title":"Beyond Performance Status","volume":"32","author":"Simcock","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1136\/ijgc-2024-005982_bb0240","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2024-005982_bb0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-17-0496","article-title":"Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study","volume":"178","author":"Klaver","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1136\/ijgc-2024-005982_bb0250","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-14-0586","article-title":"Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI)","volume":"172","author":"Van Caenegem","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1136\/ijgc-2024-005982_bb0255","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1210\/clinem\/dgaa546","article-title":"Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals","volume":"106","author":"Cheung","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:35:23Z","timestamp":1744504523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1048891X25001380"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005982","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/ijgc-2024-005982.supp1","asserted-by":"subject"}]},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 IGCS and ESGO 2024. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}